文献速递重症综合管理与镇静镇痛消化、代谢与肾脏急症

白蛋白治疗与急性肾损伤患者预后之间的关联:基于MIMIC-IV数据库的回顾性研究

[Association between albumin treatment and the prognosis of acute kidney injury patients: a retrospective study based on the MIMIC-IV database].
PubMed 文献 · Zhonghua Wei Zhong Bing Ji Jiu Yi Xue · 2025-01-01
一句话结论在MIMIC-IV的6390例ICU急性肾损伤患者中,白蛋白输注组ICU死亡风险低于未输注组(HR=0.69,95%CI 0.60-0.80)。

该研究基于美国MIMIC-IV数据库回顾性分析6390例ICU急性肾损伤患者,其中白蛋白输注组1721例、未输注组4669例,主要终点为ICU死亡率。原始数据单因素和多因素Cox回归显示白蛋白输注组死亡风险显著低于未输注组(HR=0.69,95%CI 0.60-0.80,均P<0.05),倾向性评分匹配和逆概率加权处理后结果趋势一致(均P<0.05)。Kaplan-Meier曲线显示白蛋白输注组ICU期间累积生存率显著高于未输注组(24.48% vs. 12.17%,Log-Rank检验χ²=74.26,P<0.05)。亚组分析显示,在使用血管活性药物、合并脓毒症、无肝病的急性肾损伤患者中,白蛋白输注的生存获益更显著。

要点

  • 在6390例ICU急性肾损伤患者中,白蛋白输注组1721例、未输注组4669例,白蛋白输注组ICU死亡风险低于未输注组(HR=0.69,95%CI 0.60-0.80,均P<0.05)。
  • 倾向性评分匹配和逆概率加权处理后,白蛋白输注与ICU死亡风险的关联趋势与原始数据一致(均P<0.05)。
  • 白蛋白输注组ICU期间累积生存率为24.48%,未输注组为12.17%,Log-Rank检验χ²=74.26,P<0.05。
  • 亚组分析显示,使用血管活性药物、合并脓毒症、无肝病的急性肾损伤患者从白蛋白输注中获得的生存获益更显著。

适用人群与场景

  • 美国MIMIC-IV数据库中重症监护病房的急性肾损伤患者,共6390例,其中白蛋白输注组1721例、未输注组4669例。
  • 亚组分析按患者年龄、性别和合并症进行,结果显示使用血管活性药物、合并脓毒症、无肝病的急性肾损伤患者生存获益更显著。

研究设计与关键结果

  • 研究类型为基于MIMIC-IV数据库的回顾性研究,纳入6390例ICU急性肾损伤患者,白蛋白输注组1721例、未输注组4669例,主要终点为ICU死亡率。
  • 原始数据单因素和多因素Cox回归分析显示,白蛋白输注组死亡风险显著低于未输注组(HR=0.69,95%CI 0.60-0.80,均P<0.05)。
  • 倾向性评分匹配和逆概率加权处理后结果与原始数据趋势一致(均P<0.05)。
  • Kaplan-Meier生存曲线显示白蛋白输注组ICU期间累积生存率显著高于未输注组(24.48% vs. 12.17%,Log-Rank检验χ²=74.26,P<0.05)。
  • 亚组分析显示,白蛋白输注对使用血管活性药物、合并脓毒症、无肝病的急性肾损伤患者生存获益更显著。

证据类型、等级与局限

  • 证据类型:基于MIMIC-IV数据库的回顾性研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,白蛋白输注可降低急性肾损伤患者的ICU死亡率。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

OBJECTIVE: To assess the impact of albumin (Alb) administration on the prognosis of patients with acute kidney injury (AKI).

METHODS: Clinical data of AKI patients in the intensive care unit (ICU) were retrospectively analyzed from the American Medical Information Mart of Intensive Care-IV (MIMIC-IV), including demographic data, acute physiology score (APS), comorbidities, vital signs, laboratory indicators, treatment status, ICU length of stay, and outcome indicators. The main outcome measure is ICU mortality. AKI patients were divided into Alb infusion group and Alb non infusion group based on whether they received Alb treatment. Multiple imputation was used to process missing data and eliminate variables that missing more than 30%. To ensure the stability of the results, propensity score matching (PSM) and inverse probability weighting (IPW) were used to correct the results. Using Kaplan-Meier survival curve and Cox proportional hazards regression model to evaluate the effect of Alb infusion on ICU survival rate in AKI patients. Perform subgroup analysis based on patient age, gender, and comorbidities to evaluate the prognostic effects of Alb on different patient subgroups.

RESULTS: A total of 6 390 AKI patients were included, including 1 721 in the Alb infusion group and 4 669 in the Alb non infusion group. After adjusting for key covariates in the Cox regression model, compared with the Alb non infusion group, patients in the Alb infusion group were significantly younger in age, with APS III score, proportion of vasoactive drugs and continuous renal replacement therapy (CRRT) use, sepsis proportion, heart rate, respiratory frequency, aspartate aminotransferase (AST), alanine aminotransferase (ALT), creatinine (Cr), lactic acid (Lac), and arterial partial pressure of carbon dioxide (PaCO2) levels significantly higher. The proportion of hypertension, myocardial infarction, and congestive heart failure, as well as blood pressure, urine output, platelet count (PLT), and Alb levels were significantly lower. The results of univariate and multivariate Cox regression analysis on the raw data showed that the risk of death in the Alb infusion group was significantly lower than that in the Alb non infusion group [hazard ratio (HR) = 0.69, 95% confidence interval (95%CI) was 0.60-0.80, all P < 0.05]. The results after propensity score matching (PSM) and inverse probability weighting (IPW) processing are consistent with the original data trend (both P < 0.05). The Kaplan-Meier survival curve showed that the cumulative survival rate during ICU stay in the Alb infusion group was significantly higher than that in the Alb non infusion group (24.48% vs. 12.17%, Log-Rank test: χ2 = 74.26, P < 0.05). Subgroup analysis shows that Alb infusion has a more significant survival benefit for AKI patients who use vasoactive drugs, have concurrent sepsis, and do not have liver disease.

CONCLUSION: Albumin infusion can decrease the ICU mortality of AKI patients.

来源:Zhonghua Wei Zhong Bing Ji Jiu Yi Xue,查看原文。版权归原作者所有。

参考来源

  1. Zhang X, Zhuang Y, Dai L, et al. [Association between albumin treatment and the prognosis of acute kidney injury patients: a retrospective study based on the MIMIC-IV database]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2025. PMID: 40202000. doi:10.3760/cma.j.cn121430-20230901-00723

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。